Flutemetamol (18F): Difference between revisions
Jump to navigation
Jump to search
Rabin Bista (talk | contribs) Created page with "{{DISPLAYTITLE:Flutemetamol (<sup>18</sup>F)}} {{Infobox drug | drug_name = Flutemetamol (<sup>18</sup>F) | IUPAC_name = 2-[3-(<sup>18</sup>F)Fluoro-4-(methylam..." |
Rabin Bista (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Flutemetamol (<sup>18</sup>F)}} | {{DISPLAYTITLE:Flutemetamol (<sup>18</sup>F)}} | ||
{{Infobox drug | {{Infobox drug new | ||
| drug_name = Flutemetamol (<sup>18</sup>F) | | drug_name = Flutemetamol (<sup>18</sup>F) | ||
| IUPAC_name = 2-[3-(<sup>18</sup>F)Fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol | | IUPAC_name = 2-[3-(<sup>18</sup>F)Fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol | ||
Revision as of 22:42, 14 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Flutemetamol (18F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.[1]
Mechanism of action
After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).[1]